Effect of metformin on metabolic improvement and gut microbiotaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined how metformin affects gut microbiota composition and metabolic markers in mice fed a high-fat diet to induce obesity. They compared microbiota in metformin-treated versus untreated high-fat-diet mice.
How was it studied?
Fecal microbiota composition was profiled in high-fat-diet mice with and without metformin treatment, alongside serum glucose, body weight, and cholesterol measurements. The team also tested whether metformin directly promoted Akkermansia muciniphila growth in brain heart infusion medium in vitro.
What did they find?
Metformin improved serum glucose, body weight, and total cholesterol in the high-fat-diet mice. Akkermansia muciniphila (12.44%±5.26%) and Clostridium cocleatum (0.10%±0.09%) abundances rose significantly, and A. muciniphila also increased in metformin-supplemented culture medium. Metformin treatment was linked to upregulation of 18 KEGG gut microbial metabolic pathways, including sphingolipid and fatty acid metabolism.
Why it matters
The findings suggest metformin's metabolic benefits in obesity and type 2 diabetes involve shifts in gut microbiota composition and function, not just host physiology.